Sputnik V manifested 70.5% efficacy against Delta variant half a year after vaccination - research

MOSCOW. Feb 2 (Interfax) - Russia's Sputnik V coronavirus vaccine manifested 70.5% efficacy against Covid-19 symptoms half a year after vaccination amid the Delta variant's prevalence, as follows from amendments to the vaccine use guidelines published on the Russian State Register of Medicinal Substances on Wednesday.

"Phase III of a randomized placebo-controlled clinical trial has shown that the vaccine is 91% efficacious against coronavirus infection symptoms for the wild (Wuhan) strain and 70.5% amid the Delta variant's prevalence half a year later," the document says.

During a half-year period of monitoring the trial subjects, the vaccine's efficacy in preventing severe symptoms of the disease remained at the level of 88%, it said.

Health Minister Mikhail Murashko said on August 11, 2021 that Sputnik V's efficacy was 83% in preventing the infection with the Delta variant of coronavirus and over 95% in preventing severe symptoms of Covid-19.